Publications
3 shownCD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
The macrophage checkpoint inhibitor 5F9 combined with rituximab showed promising activity in patients with aggressive and indolent lymphoma. No clinically significant safety eve...
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 3
- Citations
- 1,190
- Institution
- University of Chicago
External Links
Identifiers
- ORCID
- 0000-0002-2967-6448
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.